Company announces results from the Phase 3 COV-BARRIER study of baricitinib in hospitalised COVID-19 patients

RCT (n=1525) did not meet statistical significance on primary endpoint (progression to invasive or non-invasive ventilation or death). However, baricitinib in addition to standard of care, including steroids and remdesivir led to 38% reduction in mortality by Day 28 (p=0.0018).

Biospace Inc.